IMUNOFAN Solution for Injection

IMUNOFAN Solution for Injection  intended for intramuscular and subcutaneous administration. 

Imunofan is synthesized on the basis of the natural peptide hormone of the thymus gland - thymopoietin. The drug contains as an active pharmacological substance a peptide, which is a chain of six amino acid residues.

Imunofan is not an immune stimulant, just like an immunosuppressant. Imunofan has a modulating effect - it returns immunity indicators to the boundaries of reference values. It increases low and reduces the activity of elevated indicators, ensuring the safety of the drug, as well as the effectiveness and balance of the body's immune response.

Main components: arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine diacetate (in terms of 100%, anhydrous, free from acetic acid substance) - 45 mcg;

Excipients: (glycine 5 mg, sodium chloride 9 mg, water for injection up to 1 ml)

Pharmacotherapeutic group: immunomodulatory agent

Action:

The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. The pharmacological action is based on the achievement of three main effects: correction of the immune system, restoration of the balance of the body's oxidative-antioxidant reaction and inhibition of multidrug resistance mediated by proteins of the cell's transmembrane transport pump.

The action of the drug begins to develop within 2-3 hours after administration (fast phase) and lasts up to 4 months (medium and slow phases).
During the fast phase (starts after 2-3 hours, duration - up to 2-3 days), the detoxification effect is manifested primarily: the antioxidant defense of the body is enhanced by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes the level of lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, followed by a decrease in the concentration of cholesterol in the blood and the production of inflammatory mediators. With toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the concentration of bilirubin in the blood serum.
During the middle phase (begins after 2-3 days, duration - up to 7-10 days) there is an increase in the reactions of phagocytosis and the death of intracellular bacteria and viruses.
During the slow phase (begins on the 7-10th day, duration up to 4 months), the immunoregulatory effect of Imunofan is manifested - the restoration of disturbed indicators of cellular and humoral immunity. During this period, there is a normalization of the immunoregulatory index, there is an increase in the production of specific antibodies. The influence of Imunofan on the production of specific antiviral and antibacterial antibodies is equivalent to the action of some therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reaginic IgE antibodies (immunoglobulin E) and does not enhance the immediate hypersensitivity reaction. The drug stimulates the formation of IgA (immunoglobulin A) with its congenital deficiency.
Imunofan effectively suppresses multidrug resistance of tumor cells and increases their sensitivity to the action of cytostatic drugs.

Indications:

In adults, as an adjuvant for vaccination against bacterial and viral infections.
Prevention of exacerbation of chronic infectious and inflammatory diseases of various etiologies occurring against the background of immunodeficiency in adults and children over 2 years of age: chronic viral hepatitis, brucellosis.
Prevention of the development of toxicosis in children older than 2 years with malignant diseases of the hematopoietic and lymphoid tissues during a course of chemoradiotherapy.
Treatment as part of complex therapy for secondary immunodeficiency and toxic conditions caused by the following diseases.
In adults:
- in the complex therapy of oncological diseases in the scheme of radical combined treatment (chemoradiotherapy and surgery), in complex or symptomatic therapy in patients with a widespread tumor process (stages III-IV) of various localization;
- in the complex therapy of chronic viral hepatitis, chronic brucellosis;
- in the complex therapy of HIV infection, opportunistic infections (cytomegalovirus, herpetic infections, toxoplasmosis, chlamydia, pneumocystosis, cryptosporidiosis);
- in the treatment of III-IV degree burns with symptoms of toxemia, septicotoxemia, in surgical patients with septic endocarditis, cholecystopancreatitis, long-term non-healing wounds of the extremities, purulent-septic complications;
- in the complex therapy of broncho-obstructive syndrome, rheumatoid arthritis, psoriasis.
In adults and children over 2 years of age:
- in the complex therapy of inflammatory eye diseases;
- in the treatment of diphtheria, diphtheria bacteriocarrier.
In children older than 2 years:
- in the complex therapy of papillomatosis of the larynx and oropharynx.

Contraindications:

Hypersensitivity, pregnancy complicated by Rhesus conflict, children under 2 years of age.

Pregnancy and lactation: 

During pregnancy and during breastfeeding, it is used only if the intended benefit to the mother outweighs the potential risk to the fetus and child.

Dosage form:

Colorless transparent liquid.

Dosage and administration:

Imunofan is used subcutaneously or intramuscularly in a single dose of 45 mcg. The maximum daily dose is 45 mcg.
The drug is used in courses, depending on the purpose of the application and the nature of the disease.

IN ADULTS

As an adjuvant for vaccination against bacterial and viral infections - once at a dose of 45 mcg intramuscularly or subcutaneously on the day of vaccination.
In the complex treatment of cancer patients: in the regimen of radical combined treatment, once a day, a course of 8-10 injections before chemo-radiation therapy and surgery, followed by continuation of the course throughout the entire period of treatment.
- in patients with a widespread tumor process - once daily, with a course of 8-10 injections, with a break of 15-20 days and repeating the course during the entire subsequent period of treatment.
In the complex treatment of patients with chronic viral hepatitis and brucellosis:
- once a day, the course of treatment is 15-20 injections.
In the complex therapy of HIV infection and opportunistic infections:
- once a day, the course of treatment is 15-20 injections. If necessary, it is possible to repeat the course in 2-4 weeks.
In surgical patients, in the treatment of III-IV degree burns with symptoms of toxemia, septicotoxemia, in surgical patients with septic endocarditis, cholecystopancreatitis, long-term non-healing wounds of the extremities, purulent-septic
complications:
- once a day, the course of treatment is 7-10 injections, if necessary, the course of the drug can be extended to 20 injections.
With broncho-obstructive syndrome, rheumatoid arthritis:
- once every 3 days, the course of treatment is 8-10 injections, if necessary, the course of treatment can be extended to 20 injections.
In the complex therapy of psoriasis:
- once a day, the course of treatment is 15-20 injections.

IN ADULTS AND CHILDREN OVER 2 YEARS OF AGE

In complex therapy inflammatory diseases of the eyes:
with damage to the anterior parts of the eye (keratitis, keratouveitis) once a day, the course of treatment is 7-10 injections;
with damage mainly to the posterior parts of the eye (peripheral, posterior uveitis, retinovasculitis) and generalized inflammatory processes once a day, the course of treatment is 15-20 injections.
In the treatment of diphtheria:
- once a day, the course of treatment is 8-10 injections. With diphtheria bacteriocarrier - once every 3 days, per course - 3-5 injections.
In the complex therapy of children with papillomatosis of the larynx oropharynx in children older than 2 years:
- once a day, the course of treatment - 10 injections.
For prevention: exacerbations of chronic viral hepatitis and chronic brucellosis in adults and children over 2 years of age
- daily once a course of 15-20 injections, repeated preventive courses are recommended every 2-3 month;
development of toxicosis in children older than 2 years with malignant diseases of the hematopoietic and lymphoid tissue
- once a day, the course of treatment is 10-20 injections, during and after the end of the course of chemo-radiation therapy.

Side effects: allergic reactions to the components of the drug.

Drug interaction: the action of Imunofan does not depend on the production of PGE2 and the administration of the drug is possible in combination with anti-inflammatory (steroidal and non-steroidal) drugs.

Special instructions: as a result of the activation of phagocytosis, a short-term exacerbation of foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.

Influence on the ability to drive vehicles and mechanisms: The drug does not affect the ability to drive vehicles, mechanisms.

Storage temperature 2℃ to 8℃

Guaranteed authenticity and quality:

100% Original from LLP BIONOKS (Russia)

Patents and sertificates:

The drug contains as an active pharmacological substance a peptide representing a chain of six amino acid residues, the composition and sequence of which are protected by RF patent No. 2062096.

LLP BIONOKS (Russia)